After completing this activity, learners will be able to
• Assess efficacy and safety of current and recently approved agents to incorporate into second- and third-line treatment of HER2-positive breast cancer
• Describe the challenges of creating and implementing clinical pathways for HER2-positive breast cancer
• Develop clinical pathways for HER2-positive breast cancer to optimize evidence-based and cost effective second- and third- line treatments